| Abstrakt: |
Summary objective Antithyroid drugs are effective in some patients with Graves’ disease but not in others. The factors responsible for this difference are still unknown. We examined the relationship between the nature of anti-TSH receptor (TSH-R) antibodies and responsiveness to drugs in Graves’ disease. patients Twenty-eight untreated patients with Graves’ disease were treated with thiamazole and followed for up to 13 years. measurement Antithyroid microsomal antibodies (MCHAs) and antithyroglobulin antibodies (TGHAs) were measured by the passive haemagglutination method. Anti-TSH-R antibodies were measured by a radioreceptor assay (TBII), and thyroid-stimulating antibodies (TSAbs) and TSH-stimulation blocking antibodies (TSBAbs) were measured by bioassays using FRTL-5 cells. Blocking antibodies were also measured by the conversion assay. In order to confirm the usefulness of the conversion assay, in vitro experiments using mixtures of TSAb serum and TSBAb serum were performed. results In in vitro conversion experiments, the conversion assay sensitively detected coexisting blocking antibodies. TSBAb was found in seven patients and a positive conversion ratio was found in four patients, and, of these, three patients had both antibodies. Finally, eight patients (28·6%) had blocking antibodies and 25 of 28 patients (89·3%) had stimulating antibodies. These patients with blocking antibodies (Group A) responded well initially to antithyroid drugs and showed earlier normalization of the serum T4 level (3·0 ± 1·2 weeks) than patients without blocking antibodies (Group B, 10·7 ± 8·5, P < 0·001). Unexpectedly, remission of Graves’ thyrotoxicosis was earlier in Group B (5·1 ± 4·4 years) than in Group A (8·0 ± 4·3 years, P < 0·05). Other parameters, including serum T4, goitre size, ophthalmopathy, TBII, TSAb, TGHA and MCHA, were not different between the two groups.... [ABSTRACT FROM AUTHOR] |
Plný text